Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Cocrystal Pharma, Inc. issued 2,764,710 shares of common stock to accredited investors for at a price of $1.70 per share.
- Security
- common stock
- Shares
- 2,764,710 shares
- Purchaser
- accredited investors
- Consideration
- at a price of $1.70 per share
Exact text from the filing
in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $1.70 per share (the “Registered Direct Offering”) and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Cocrystal Pharma, Inc. issued warrants to purchase up to an aggregate of 5,529,420 shares of warrant to accredited investors for initial exercise price of $1.50 per share.
- Security
- warrant
- Shares
- warrants to purchase up to an aggregate of 5,529,420 shares
- Purchaser
- accredited investors
- Consideration
- initial exercise price of $1.50 per share
Exact text from the filing
and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 5,529,420 shares of Comon Stock (“the Investor Warrants”), at an initial exercise price of $1.50 per share (the “Private Placement” and together with the Registered Direct Offering, the “Offering”). The Shares were offered at-the-market under rules of The Nasdaq Stock Market,
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Cocrystal Pharma, Inc. issued warrants to acquire up to an aggregate of 207,353 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses.
- Security
- warrant
- Shares
- warrants to acquire up to an aggregate of 207,353 shares of Common Stock
- Purchaser
- H.C. Wainwright & Co., LLC
- Consideration
- cash fee equal to 7.0% of the aggregate gross proceeds, a management fee equal to 1.0% of the aggregate gross proceeds, reimbursement of certain expenses
Exact text from the filing
medicines for use in the treatment of human viral diseases. 2 Under the SPA, no later than October 10, 2025, the Company is required to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued or issuable upon exercise of the Investor Warrants (the “Resale Registration Statement”). The Company is required to
View on SEC.gov